SYRS - Syros Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.11
-0.16 (-2.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.27
Open7.24
Bid6.73 x 800
Ask8.11 x 2200
Day's Range7.03 - 7.47
52 Week Range6.30 - 17.50
Volume74,970
Avg. Volume121,164
Market Cap239.283M
Beta (3Y Monthly)-2.01
PE Ratio (TTM)N/A
EPS (TTM)-1.99
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.33
Trade prices are not sourced from all markets
  • Simply Wall St.22 days ago

    Who Are The Major Shareholders Of Syros Pharmaceuticals Inc (NASDAQ:SYRS)?

    The big shareholder groups in Syros Pharmaceuticals Inc (NASDAQ:SYRS) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller Read More...

  • Business Wire24 days ago

    Syros to Present at 2018 Cantor Global Healthcare Conference

    Syros Pharmaceuticals (SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the 2018 Cantor Global Healthcare Conference. Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes.

  • Business Wirelast month

    Syros to Present at Morgan Stanley 16th Annual Global Healthcare Conference

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Morgan Stanley 16th Annual Global Healthcare Conference.

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Cree, ArcBest, Syros Pharmaceuticals, Aegion, Adecoagro S.A, and Nevsun Resources — Future Expectations, Projections Moving into 2018

    NEW YORK, Aug. 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cree, ...

  • Business Wire2 months ago

    Syros to Present at 2018 Wedbush PacGrow Healthcare Conference

    Syros Pharmaceuticals (SYRS), a biopharmaceutical company pioneering the development of medicines that control the expression of genes, today announced that its Chief Financial Officer Joseph J. Ferra will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference. Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes.

  • Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Misses Revenue Estimates

    Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 12.24% and -71.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire2 months ago

    Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

    Plan to Open Expansion Cohorts in Phase 1 Trial of SY-1365 in Fall of 2018; Expansion to Focus on Ovarian and Breast Cancer Patient Populations as Single Agent and in Combination

  • ACCESSWIRE2 months ago

    Syros Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Syros Pharmaceuticals, Inc. (NASDAQ: SYRS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...

  • Business Wire3 months ago

    Syros to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018

    Syros Pharmaceuticals (SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 7, 2018 to report its second quarter 2018 financial results and provide a corporate update. Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.

  • GlobeNewswire3 months ago

    Investor Expectations to Drive Momentum within ShotSpotter, Kohl's, Cheniere Energy Partners LP, Palo Alto Networks, Syros Pharmaceuticals, and Ryman Hospitality Properties — Discovering Underlying Factors of Influence

    NEW YORK, July 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ShotSpotter ...

  • Business Wire3 months ago

    Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018

    Syros Pharmaceuticals (SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that it will host a key opinion leader (KOL) breakfast symposium focused on the unmet need, treatment landscape and opportunity for new combination approaches in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) from 8:30-10:30 a.m. ET on Tuesday, July 17, 2018 in New York City. Syros is currently evaluating SY-1425, its first-in-class, selective retinoic acid receptor alpha (RARα) agonist, in a Phase 2 clinical trial in combination with standard-of-care and targeted therapies in genomically defined subsets of AML and MDS patients.

  • 2 Stable and 2 Speculative Biotech Stocks to Buy
    InvestorPlace4 months ago

    2 Stable and 2 Speculative Biotech Stocks to Buy

    Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.

  • Business Wire4 months ago

    Syros Announces Appointment of Michael W. Bonney to Its Board of Directors

    Syros Pharmaceuticals (SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced the appointment of Michael W. Bonney to the Company’s Board of Directors. Mr. Bonney brings extensive strategic, operational, commercial and leadership experience in the biotechnology industry. “Mike is a highly regarded and accomplished leader with a proven record of building successful commercial enterprises based on a strong strategic vision, operational excellence and a passion for bringing important therapies to market for patients,” said Nancy Simonian, M.D., Chief Executive Officer of Syros.

  • Business Wire5 months ago

    Syros to Present at Upcoming Investor Conferences

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at upcoming investor conferences.

  • Business Wire5 months ago

    Syros to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at Upcoming ASCO Annual Meeting

    Syros Pharmaceuticals (SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that the Company will present on the design of its Phase 1 clinical trial of SY-1365, a first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 1-5, 2018 in Chicago. The Phase 1 trial is currently enrolling advanced solid tumor patients in the dose-escalation portion of the trial, with planned expansion cohorts to further evaluate SY-1365 as a single agent and in combination with standard-of-care therapies in multiple ovarian and breast cancer patient populations.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of SYRS earnings conference call or presentation 10-May-18 12:30pm GMT

    Q1 2018 Syros Pharmaceuticals Inc Earnings Call

  • Business Wire5 months ago

    Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today reported financial results for the quarter ended March 31, 2018 and provided an update on recent accomplishments and upcoming events.

  • Business Wire6 months ago

    Syros to Report First Quarter 2018 Financial Results on Thursday, May 10, 2018

    Syros Pharmaceuticals (SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 10, 2018 to report its first quarter 2018 financial results and provide a corporate update. Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control the expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.

  • Business Wire6 months ago

    Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced new preclinical data showing that SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase 1 trial in patients with advanced solid tumors, demonstrated potent anti-tumor activity in multiple models of heavily ...

  • Incyte Advances R&D Strategy with Multiple Partnerships
    Market Realist6 months ago

    Incyte Advances R&D Strategy with Multiple Partnerships

    In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN), which was later amended in February 2017. As per the amended agreement, the ongoing research programs for the development of checkpoint modulator antibodies targeted at GITR and OX40 have been converted from co-funded ones to being fully funded by Incyte. Additionally, the profit-sharing arrangement for these research programs has been converted into royalty-bearing programs.

  • Incyte’s Collaborations and Developments in 2018
    Market Realist7 months ago

    Incyte’s Collaborations and Developments in 2018

    Incyte (INCY) has a well-established distribution network in the US and sells Jakafi and Iclusig in the country through its own network. For sales outside the US market, the company entered into an agreement with Novartis (NVS) to develop and commercialize Jakafi. Novartis sells Jakafi under the name of Jakavi, and Incyte receives royalties on the total sales of Jakavi. The chart below compares the royalty revenues and contract revenues for Incyte since 1Q16.

  • Business Wire7 months ago

    Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting

    Syros Pharmaceuticals , a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that the Company and its collaborators from the Dana-Farber Cancer Institute will present new preclinical data on SY-1365, a first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase 1 trial in patients with advanced solid ...